

Subject Index

- Acetylcholine, 385
 induction of catecholamine enzymes, 264
- Actinomycin D, 216
- Adenosine triphosphate
 norepinephrine levels, 428
- Adenyl cyclase, 400
 brain, 403
 distribution, 427
 glial cells, 427
 prostaglandin, 427
- Adipose tissue, 400
- Adrenal cortex, 367
 epinephrine, 412
- Adrenal gland
 denervation, 394
 ACTH, 411
- Adrenal medulla
 acetylcholine excitation, 385
 catecholamine storage, 418
 dopamine- β -hydroxylase, 394
 muscarinic receptors, 385
 nicotinic receptors, 385
 secretion from, 385
 tyrosine hydroxylase, 394
- Adrenergic receptors, 365
- Adrenocorticotrophic hormone, 366, 401, 411
- D-Amino acid oxidase, 350
- Amino acid uptake, 383
- Amylase release, 401
- Angiotensin, 411
- Antibodies
 dopamine- β -hydroxylase, 311
- Aromatic L-amino acid decarboxylase
 antisera, 253, 284
 cold exposure, 356
 distribution of, 361
 L-dopa, effect on, 279
 erythrocyte, 282
 immunofluorescence, 294
 inhibitors, 274, 340, 371, 429
 localization, 168
 purification, 293
- ATP, 387
- ATPase, 390
- Axonal transport, 245
- Axotomy, 375
- Biopterin, 363
- Blood vessels, 223
 dopamine- β -hydroxylase, 322
- Bretylium, 213
 catecholamine synthesis, 213
 norepinephrine release, 213
 tyrosine hydroxylase, 214
- Calcium, 368, 385
- Cardiac contractile force, 400
- Catecholamines
 assay, 176
 brain, 373, 379
 degradation, 203
 from administered L-dopa, 272
 secretion, 385
 synthesis, 207
 turnover, 223, 226, 374
- Catechol-O-methyl transferase
 L-dopa, effect on, 287
 in vasculature, 195
 thyroid effect on, 366
- Central nervous system, 313
- Cerebral hemisection, 377
- Chlorisondamine, 366
- Chlorpromazine, 381
- Choline acetyltransferase, 259
- Chromaffin cells
 dogfish, 412
 mammals, 411
- Chromaffin granules, 386
- Chromogranins, 238, 387
- Cocaine
 catecholamine synthesis, 215
 potentiation, 193
- Colchicine, 291
- Cold exposure, 256
- Copper deficiency, 355, 363
- Cycloheximide
 catecholamine synthesis, 216
- Cyclic 3',5'-adenosine monophosphate, 365,
 389, 399
 beta-adrenergic receptors, 401
 blood platelets, 427
 brain slices, 403
 histamine receptors, 403
 Purkinje cells, 406
- Cytochalasin B, 291
- Decentralization, 259, 261
- Dense core vesicles, 292
- Depression, endogenous, 360
- Desmethylimipramine, 193

- 3,4-Dihydroxyphenylpyruvic acid, 362
 transamination to dopa, 350
 Dihydropteridine reductase, 363
 6,7-Dimethyl-5,6,7,8-tetrahydropteridine
 catecholamine synthesis, 217
 K_m value: tyrosine hydroxylase, 211
 stimulation of catecholamine synthesis,
 209
 Dopa (3,4-dihydroxyphenylalanine), 227
 accumulation in tissue, 371
 administration, 362
 brain, 272, 372
 catecholamine biosynthetic enzymes, 200,
 272, 281, 287
 D isomer, 350
 Parkinson's disease, 279, 292
 pentobarbital sleep time, 286
 pyridoxine deficiency, 350
 tissue levels, 274
 tyrosine hydroxylase, effect on, 270
 Dopa decarboxylase (see aromatic L-amino
 acid decarboxylase)
 Dopamine, 275, 277, 284
 Dopamine- β -hydroxylase 225, 295
 antibodies, 311
 assay, 234, 291
 blood vessels, 321, 361
 central nervous system, 313
 cold stress, 291
 cofactors, 206
 distribution of, 36
 L-dopa, effect on, 286
 dopaminergic pathways, 320
 familial dysautonomia, 241, 303
 hormonal regulation, 237
 hypertension, 291
 immunochemistry, 247, 361
 immunofluorescent staining, 361
 induction, 235
 inhibitors, 277
 localisation, 168, 206
 plasma, 240, 291, 300
 radioisotopic assay, 234
 regulation, 233
 release, 238
 serum, 298
 synthesis, 323
 turnover, 246, 256
 vas deferens, 368
 vesicles, 312, 387
 End plate potentials, 405
 End product inhibition, 223
 Epinephrine
 brain levels, 419
 frog tissues, 419
 glycogenolytic action, 399
 hypophysectomy, effect of, 419
 synthesis, 418
 Erythrocyte decarboxylase activity, 282
 Excitation-secretion coupling, 388
 Exocytosis, 167
 Feedback inhibition, 380
 Ganglia cultures, 251
 Ganglionic blockade, 403
 Ganglionic blocking agents, 269, 366
 Glucocorticoids, 366, 414
 adrenal medulla, 411
 phenylethanolamine-N-methyl transfer-
 ase, effect on, 411, 414
 Glycogenesis, 399
 Hormonal regulation, 226
 Haloperidol, 381
 Histamine, 371
 5-Hydroxytryptamine
 cerebral, 376
 spinal cord, 375
 6-Hydroxydopamine, 228, 249
 choline acetyltransferase, 263
 effect on vascular catecholamines, 199
 induction of enzymes, 291
 neuronal uptake, 192
 5-Hydroxyindoleacetic acid, 371
 3-Hydroxy phenyl pyruvic acid, 350
 5-Hydroxytryptamine, 371
 turnover in brain, 374
 5-Hydroxytryptophan, 371
 in brain, 372
 liver aromatic L-amino acid decarbox-
 ylase, 285
 Hypertension
 doca-salt induced, 367
 Hypophysectomy, 366
 adrenal, 421
 adrenal polysomes, 417
 decrease of tyrosine hydroxylase, 275
 liver aromatic L-amino acid decarboxyl-
 ase, 286
 norepinephrine levels, 418
 Imipramine, 365
 Immunoassay
 dopamine- β -hydroxylase, 312
 Immunofluorescence, 313
 Immunosympathectomy
 effect on mesenteric artery, 199

- Indoles**
brain, 378
spinal cord, 376
- Insulin**
interactions with catecholamines, 367
secretion, 387
- Iron deficiency, 363**
monoamine oxidase, 356
- Leukocytes, 388**
- Lipolysis, 400**
- Mass fragmentography**
assay of heart ventricle, 178
- Mass spectrometry assay, 175**
- Mesenteric artery**
distribution of C.A., 191
- 3-O-Methyl-dopa, 292**
- α -Methyldopamine-pentafluoropropionic anhydride, 176**
- α -Methyltyrosine, 223**
- Methylxanthines, 404**
- Microtubules, 291**
catecholamine release, 239
colchicine, 246
disrupting agents, 389
storage vesicles, 246
- Mineralocorticoids, 367**
- Monoamine oxidase**
antibodies, 311
assay of *in vivo* activity, 351, 352
binding of FAD, 352, 353
blood vessels, 195, 340
brain specific form, 328
L-dopa effect on, 286
hormonal control, 338
immunological studies, 325, 361
inhibitor resistant forms, 340
inhibitors, 285, 296
iron deficiency, 356, 357
molecular weight, 332
multiple forms, 325, 331, 362
riboflavin deficiency, 351, 352, 353
substrate specificities of multiple forms, 335
- Motor nerve stimulation, 366**
- Nerve growth factor, 227**
catecholamine synthesizing enzymes, effect on, 255, 258, 292
choline acetyltransferase, 264
effect in newborn rats, 258
- Nerve growth factor antiserum**
ability to bind complement, 263
destruction of peripheral nerves, 259
- Nerve terminals, adrenergic, 367**
- Neurofilaments, 291**
- Neuronal regulation, 226**
- Norepinephrine**
decrease of tyrosine hydroxylase, 275
feedback inhibition, 216, 217
liver aromatic L-amino acid decarboxylase, 284, 285, 286, 287
secretion, 420
turnover, 280, 366
uptake, 203, 250, 278
- Operon, 256**
- Oxygen consumption, 367**
- Pancreatic islets**
serotonin and dopamine in, 368
- Pargyline, 382**
catecholamine synthesis, 207, 209
- Pentobarbital sleep time, 286**
- N-Pentylamine, 362**
- Phentolamine, 368**
- Phenylethanolamine-N-methyl transferase**
ACTH, effect of, 412
adrenal explant, activity of, 416
adrenal medulla, 367
de novo synthesis, 417, 422
dexamethasone, effect of, 413, 416
distribution, 361
epinephrine inhibition, 417
fetal rat, 412
frog tissue, 420
glucocorticoid, effect on activity in brain, 420
hypophysectomy, 412, 421
immunochemistry, 304
immunological studies, 361
insulin, effects on, 392
methopirapone, effect of, 414
physical properties, 421
properties, 304
protein synthesis inhibitors, 416
regulation by adrenocorticoids, 257
transsynaptic elevation, 422
- Phosphorylase α**
brain, 405
- Phosphorylase β kinase, 400**
- Plasma membrane**
adenyl cyclase, 400
depolarization, 386
divalent cations, 390
fusion mechanisms, 390
- Polysomes, adrenal**
ACTH, 424
dexamethasone, 424
hypophysectomy, 424

- Prostaglandins, 365
 adrenergic transmission effect on, 368
 cyclic AMP, 368
 dopamine- β -hydroxylase release, 238
- Protein kinase, 400
- Pteridine reductase, 205
- Purkinje cells, 406
- Puromycin
 catecholamine synthesis, 215, 216
- Pyridoxal phosphate
 activation of liver decarboxylase, 213
 aromatic L-amino acid decarboxylase
 349, 350
 isoquinoline formation, 350
- Pyridoxine
 deficiency, 362
 deficiency, effect on catecholamine metabolism, 349
 parkinsonian patients, effect on, 279, 349
- Receptors, 368, 381
 beta-adrenergic, 401
- Reserpine
 aromatic L-amino acid decarboxylase, 256
 catecholamine depletion, 212
 catecholamine synthesis, 212
 effects on brain, 373
 tyrosine hydroxylase induction, 212, 270
- Riboflavin deficiency, 362
 effect on catecholamine levels, 351
 effect on monoamine oxidase activity, 351, 352, 353
- Spinal cord, 375
- Splanchnic nerve activity
 regulation of enzymes, 257
- Spontaneously hypertensive rats, 200
- Squid synapse, 389
- Steroidogenesis, 400
- Stimulus-secretion coupling, 385
- Superior cervical ganglia, 256
- Sympathectomy
 cervical, 362
- Sympathetic ganglia
 organ culture, 249, 292
- Sympathetic nerve activity
 catecholamine synthesis, 214
 decrease of tyrosine hydroxylase, 276
 induction of tyrosine hydroxylase, 276
 tyrosine hydroxylase levels, 216
 tyrosine hydroxylation, 215
- Synaptic vesicles, 167
- Tetrahydropteridine, 363
- Thyroid, 365
- Tranylecypromine, 362
- Tryptophan hydroxylation, 374
- Tryptophan hydroxylase
 spinal cord, 375
- Turnover
 cardiac norepinephrine, 365
 dopamine, 184
 norepinephrine, 170
- Tyramine
 catecholamine, synthesis, 206
 hypertension, 362
- Tyrosine
 hydroxylation, 374
 turnover rate of catecholamines, 169
- Tyrosine amino transferase, 229
- Tyrosine hydroxylase, 363
 adrenal, 194
 assay, 207
 in blood vessels, 194
 C. factors, 205
 catechol inhibition of, 205
 diethyldithiocarbamate, 354
 distribution of enzyme, 273
 drug induction, 225
 effect of L-dopa, 200
 enzyme turnover, 273
 feedback inhibition, 363, 380
 heart, 194
 induction, 255, 269, 407
 inhibitors and activators, 272, 273
 insulin, effect on, 392
 K_m values following L-dopa, 273
 localization, 204, 205
 regulation by end product inhibition, 269
 turnover, 256
- Uterus, 367
- Vas deferens, 207
- Vesicles, 387
 enzymes in, 312, 387